Article Text

Download PDFPDF
Drug survival on TNF inhibitors: 2003–2004 data from Italian National Register (GISEA Register)
  1. Florenzo Iannone1,
  2. Gianfranco Ferraccioli2,
  3. Elisa Gremese2,
  4. Giovanni Lapadula1,
  5. for the Gruppo Italiano di Studio sulle Early Arthritides (GISEA)
  1. 1Rheumatology Unit, University of Bari, Bari, Italy
  2. 2Università Cattolica del Sacro Cuore, Roma, Italy
  1. Correspondence to Professor Florenzo Iannone, DIM-Rheumatology Unit, University of Bari, Policlinico, Piazza G. Cesare 11, Bari 70124, Italy; f.iannone{at}

Statistics from

We read with interest the findings of the paper by Neovius et al1 recently published on Annals of the Rheumatic Diseases who retrospectively studied the drug survival on tumour necrosis factor (TNF)-α blockers in patients with rheumatoid arthritis (RA) in real-life settings. The primary endpoint of their analysis was to assess the drug discontinuation rates in RA patients starting a first ever TNF-α inhibitor and to compare between-group survival rates for the historical anti-TNF-α drugs, namely adalimumab, etanercept and infliximab, during 5 years of follow-up. Additionally, they also evaluated the discontinuation rates of each anti-TNF-α drug across calendar period. They selected patients starting the treatment since 2003, …

View Full Text


  • Contributors FI, GF, EG and GL gave a personal and active contribution to elaborate this comment. All the authors read and approved the final manuscript before submission.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethical Committee of Bari, Italy.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles